Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Evidence and gaps in tumor-agnostic therapies for breast cancer: a narrative review.
Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer
Published: November 01, 2025
The Adverse Effects of Artri King: A Systematic Review and Case Series.
Journal: Southern medical journal
Published: July 15, 2025
HSR25-186: A Systematic Review and Meta-Analysis of Randomized Controlled Trials to Evaluate the Risk of General Systemic Adverse Events in Locally Advanced Head and Neck Squamous Cell Carcinoma Treated With Immune Checkpoint Inhibitors.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2025
HSR25-175: Meta-Analysis of Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Venous Thromboembolism (VTE) and Immune-Related Adverse Events (iRAEs) in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Immunochemotherapy.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 29, 2025
HSR25-187: Meta-Analysis of Phase III Randomized Controlled Trials to Evaluate the Risk of Gastrointestinal Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
HSR25-152: Incidence of Hematologic Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
HSR25-176: Efficacy of Immunochemotherapy in Primary Advanced or Recurrent Endometrial Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials (RCTs).
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
HSR25-171: Risk of Health-Related Quality of Life (HRQOL) Events in Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
HSR25-198: A Systematic Review and Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Hand-Foot Skin Reaction (HFSR) or Palmar-Plantar Erythrodysesthesia (PPE) in Patients With Cancers Treated With Fruquintinib.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
HSR25-150: Meta-Analysis of Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Health-Related Quality of Life (HRQOL) Events in Patients with Primary Advanced or Recurrent Endometrial Cancer Treated With First-Line Immunochemotherapy.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
HSR25-172: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Infectious Adverse Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
Last Updated: 09/26/2026